Latest news from Medicinal Chemistry
This work is the result of a collaboration between medicinal chemists, laboratory and clinician scientists at Monash University and Peter MacCallum Cancer Centre.
Dr Arisbel Batista Gondin and Dr Chris Smedley from MIPS are recipients of the 2024 ARC Discovery Early Career Researcher Award (DECRA) scheme
Prior to joining MIPS, Brendon was the Chief Scientific Officer of Canthera Discovery.
The Commonwealth Government’s Medical Research Future Fund (MRFF) National Critical Research Infrastructure Grant has invested $9.75 million into establishing MedChem Australia.
The MIPS group will focus on responding to the risk of viral and bacterial replication through the development of a platform capability in polynucleotide fragment based drug design that is better able to discover small-molecules for targeting RNA
From the age of 14, Professor Paul Stupple knew he wanted to be a medicinal chemist and go on to work for a large pharmaceutical company. In 2000 Professor Stupple achieved his lifelong goal when he joined Pfizer, an experience that enabled him to
QPX9003, a novel antibiotic developed by Monash University researchers targeting antibiotic-resistant ‘superbugs’ has achieved an important milestone in its clinical development, with the initial Phase 1 studies of the drug delivering
A Monash-led team of researchers has been funded $3.8 million in the current round of Medical Research Future Fund to develop a new class of drug compounds to counter drug-resistant epilepsy.